Want to create an interactive transcript for this episode?
Podcast: Share Talk LTD
Episode: Zak Mir talks to Adrian Kinkaid, CEO (AIM:FAB) Fusion Antibodies
Description:
Fusion Antibodies plc (AIM: FAB), as the Early Discovery Contract Research Organisation specialising in pre-clinical antibody discovery, announces its unaudited interim results for the six months ended 30 September 2023 and provides an update on recent commercial progress.
Operational highlights
·  Increased numbers of commercial opportunities identified and improving pipeline valuation
·  A number of projects delayed by clients as they seek further investment
·  Progress in development of the OptiMAL® library, with demonstration of whole IgG antibodies expressed on the cell surface
·  £1.67 million fundraise alongside £1.6 million cost rationalisation exercise
·  Appointment of Stephen Smyth as interim C...